Skye Bioscience, Inc. Common Stock Net Assets
Skye Bioscience, Inc. Common Stock net assets. Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has net assets worth $-497.31K USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.03 Million) and total liabilities ($11.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Skye Bioscience, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-497.31K |
| % of Total Assets | -4.51% |
| Annual Growth Rate | 61.77% |
| 5-Year Change | 241.47% |
| 10-Year Change | N/A |
| Growth Volatility | 524.92 |
Net Assets of Skye Bioscience, Inc. Common Stock (2012–2025)
Net assets of Skye Bioscience, Inc. Common Stock from 2012 to 2025. This chart illustrates how Skye Bioscience, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See SKYE net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual net assets of Skye Bioscience, Inc. Common Stock from 2012 to 2025. For live market cap and overall valuation, see Skye Bioscience, Inc. Common Stock (SKYE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $20.02 Million | -70.62% |
| 2024-12-31 | $68.15 Million | +3296.88% |
| 2023-12-31 | $-2.13 Million | +29.13% |
| 2022-12-31 | $-3.01 Million | -151.30% |
| 2021-12-31 | $5.86 Million | +1200.88% |
| 2020-12-31 | $450.79K | -17.75% |
| 2019-12-31 | $548.06K | +103.52% |
| 2018-12-31 | $-15.56 Million | -1845.09% |
| 2017-12-31 | $-800.08K | +44.86% |
| 2016-12-31 | $-1.45 Million | -408.05% |
| 2015-12-31 | $471.00K | +203.85% |
| 2014-12-31 | $-453.55K | -1143.99% |
| 2013-12-31 | $-36.46K | -194.55% |
| 2012-12-31 | $38.56K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Skye Bioscience, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40713495.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Skye Bioscience, Inc. Common Stock Net Assets Breakdown (December 2025)
Skye Bioscience, Inc. Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $33.38K | 0.17% |
| Other Components | $206.87 Million | 1033.08% |
| Total Equity | $20.02 Million | 100.00% |
Skye Bioscience, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Robogroup
TA:ROBO
|
$5.40 Million |
|
DB ENERGY S.A. ZY -10
F:0CJ
|
$5.41 Million |
|
CN Asia Corporation Bhd
KLSE:7986
|
$5.41 Million |
|
Prolexus Bhd
KLSE:8966
|
$5.41 Million |
|
Proodeftiki S.A.
AT:PRD
|
$5.40 Million |
|
5E ADVANCED MATERIALS CDI
F:J9I0
|
$5.40 Million |
|
Ferguson Plc
LSE:FERG
|
$5.40 Million |
|
Palamina Corp
V:PA
|
$5.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Skye Bioscience, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 68,151,724 to 20,024,175, a change of -48,127,549 (-70.6%).
- Net loss of 55,924,814 reduced equity.
- Other factors increased equity by 7,797,265.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.92 Million | -279.29% |
| Other Changes | $7.80 Million | +38.94% |
| Total Change | $- | -70.62% |
Book Value vs Market Value Analysis
This analysis compares Skye Bioscience, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.30x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.14x to 0.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $9.02 | $1.22 | x |
| 2013-12-31 | $-42.60 | $1.22 | x |
| 2014-12-31 | $-86.37 | $1.22 | x |
| 2015-12-31 | $55.21 | $1.22 | x |
| 2016-12-31 | $-145.72 | $1.22 | x |
| 2017-12-31 | $-53.00 | $1.22 | x |
| 2018-12-31 | $-236.79 | $1.22 | x |
| 2019-12-31 | $8.24 | $1.22 | x |
| 2020-12-31 | $3.90 | $1.22 | x |
| 2021-12-31 | $28.84 | $1.22 | x |
| 2022-12-31 | $-0.01 | $1.22 | x |
| 2023-12-31 | $-2.43 | $1.22 | x |
| 2024-12-31 | $14.94 | $1.22 | x |
| 2025-12-31 | $4.04 | $1.22 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Skye Bioscience, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -279.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.41x
- Recent ROE (-279.29%) is below the historical average (-195.95%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 11.69% | 27.76% | 0.38x | 1.11x | $653.10 |
| 2013 | 0.00% | -35.42% | 2.33x | 0.00x | $-102.19K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.69 Million |
| 2015 | -1027.86% | 0.00% | 0.00x | 7.45x | $-4.89 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.03 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.01 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-17.64 Million |
| 2019 | 191.95% | 0.00% | 0.00x | 3.64x | $997.19K |
| 2020 | -1455.46% | 0.00% | 0.00x | 5.93x | $-6.61 Million |
| 2021 | -145.33% | 0.00% | 0.00x | 1.68x | $-9.11 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.18 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.43 Million |
| 2024 | -38.98% | 0.00% | 0.00x | 1.07x | $-33.38 Million |
| 2025 | -279.29% | 0.00% | 0.00x | 1.41x | $-57.93 Million |
Industry Comparison
This section compares Skye Bioscience, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Skye Bioscience, Inc. Common Stock (SKYE) | $-497.31K | 11.69% | N/A | $5.40 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more